NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









A2 Biotherapeutics

A2 Biotherapeutics

Private
Agoura Hills, CaliforniaHealthcare & Life Scienceshttps://www.a2bio.com/

Last Round

Grant

May 6, 2025

Total Funding Raised

$270.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

A2 Biotherapeutics is a biotechnology company that develops logic-gated cell therapies for the treatment of solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

CAR T-cell therapysolid tumor therapylogic-gated CAR Tprecision cell therapyTmod platformcell therapynext-gen CAR-Tbiotech drug discoveryoncology clinical trialson-target off-tumorHLA loss targetingcancer immunotherapyclinical-stage biotechcell engineeringsolid tumor oncology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

A2 Biotherapeutics Comparables

Compare A2 Biotherapeutics with similar companies based on industry and business-model similarity.

A2 Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ArsenalBio
89%
Eureka Therapeutics
82%
Link Cell Therapies
82%

A2 Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMay 6, 2025
Series CJan 9, 2025
Series B ExtensionDec 19, 2022
Series BOct 6, 2020
Series A ExtensionNov 5, 2019

Key People

Founding team and executive leadership

Jim Robinson

Chief Executive Officer

Executive Team

Thomas Leung

Chief Financial Officer

Executive Team

Agi Hamburger

Chief Operating Officer

Executive Team

A2 Biotherapeutics Investors

Notable investors and investment history

A2 Biotherapeutics investors
InvestorRounds
The Column GroupSeries B, Series A Extension, Series C
Perceptive AdvisorsSeries C
Vida VenturesSeries B, Series C, Series A Extension
Aisling CapitalSeries C
Casdin CapitalSeries B
Nextech InvestSeries B, Series A Extension
UC InvestmentsSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 23, 2026

    Three abstracts accepted for presentation at the 2026 ASCO Annual Meeting.

  • Oct 3, 2025

    Four abstracts accepted for the Society for Immunotherapy of Cancer meeting.

A2 Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

A2 Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about A2 Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAgoura Hills, California
Employee Range118
Year Founded2018
Last FundingMay 6, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.